Table 2.
Baseline patient characteristics associated with programme losses (deaths, loss to follow-up and transfers-out) and virological failure in multivariate Cox proportional hazard models.
| Variable | Deathsa | LTFUb | Transfers-outc | Virological failuired | ||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| AHR (95% CI) | P | AHR (95% CI) | P | AHR (95% CI) | P | AHR (95% CI) | P | |
|
| ||||||||
| Male sex | 1.48 (1.17-1.88) | 0.001 | 1.26 (1.05-1.51) | 0.014 | 0.82 (0.64-1.04) | 0.100 | - | - |
|
| ||||||||
| Age | 1.00 | - | ||||||
| ≤ 25 yrs (ref.) | 1.00 | - | 1.00 | - | - | - | 0.50 (0.36-0.69) | <0.001 |
| 26-30 yrs | 0.72 (0.44-1.17) | 0.185 | 0.74 (0.56-0.98) | 0.033 | - | - | 0.46 (0.34-0.62) | <0.001 |
| 31-40 yrs | 0.72 (0.46-1.13) | 0.158 | 0.53 (0.40-0.69) | <0.001 | - | - | 0.33 (0.23-0.47) | <0.001 |
| ≥41 yrs | 1.34 (0.85-2.12) | 0.208 | 0.48 (0.35-0.64) | <0.001 | - | - | ||
|
| ||||||||
| CD4 cell count category (cells/μl) | ||||||||
| ≤50 (ref.) | 1.00 | - | - | - | - | - | 1.00 | - |
| 51-100 | 0.57 (0.43-0.77) | <0.001 | - | - | - | - | 0.72 (0.55-0.94) | 0.018 |
| 101-150 | 0.50 (0.36-0.70) | <0.001 | - | - | - | - | 0.66 (0.49-0.89) | 0.006 |
| 151-200 | 0.40 (0.27-0.59) | <0.001 | - | - | - | - | 0.72 (0.53-0.98) | 0.034 |
| >200 | 0.41 (0.25-0.65) | <0.001 | - | - | - | - | 0.47 (0.31-0.72) | 0.001 |
|
| ||||||||
| WHO stage | ||||||||
| Stage I and II (ref.) | 1.00 | - | 1.00 | - | - | - | 1.00 | - |
| Stage III and IV | 1.94 (1.34-2.81) | <0.001 | 1.24 (1.02-1.51) | 0.031 | - | - | 1.09 (0.84-1.40) | 0.514 |
|
| ||||||||
| Log10 viral load category (copies/ml) | ||||||||
| <4 (ref.) | 1.00 | - | - | - | - | - | 1.00 | - |
| 4-4.9 | 1.06 (0.64-1.76) | 0.810 | - | - | - | - | 1.43 (0.93-2.21) | 0.106 |
| ≥5 | 1.43 (0.87-2.37) | 0.159 | - | - | - | - | 2.05 (1.32-3.18) | 0.001 |
|
| ||||||||
| Year of starting ART | ||||||||
| 2002/4 (ref.) | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
| 2004/5 | 1.41 (0.97-2.04) | 0.070 | 1.76 (1.24-2.48) | 0.001 | 2.00 (1.27-3.15) | 0.003 | 1.38 (0.98-1.95) | 0.066 |
| 2005/6 | 1.17 (0.80-1.72) | 0.420 | 3.14 (2.24-4.39) | <0.001 | 2.88 (1.82-4.55) | <0.001 | 1.48 (1.05-2.11) | 0.026 |
| 2006/7 | 1.11 (0.74-1.67) | 0.624 | 3.64 (2.54-5.22) | <0.001 | 4.34 (2.71-6.93) | <0.001 | 1.74 (1.20-2.53) | 0.004 |
| 2007/8 | 1.11 (0.71-1.72) | 0.653 | 4.86 (3.32-7.11) | <0.001 | 3.65 (2.17-6.15 | <0.001 | 2.49 (1.68-3.69) | <0.001 |
LTFU, lost to follow-up; AHR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval;P, p-value and -, no association with particular outcome
a
3012 observations
b
3132 observations
c
3134 observations
d
3012 observations